Karen Facey

3.2k total citations · 1 hit paper
50 papers, 2.2k citations indexed

About

Karen Facey is a scholar working on Economics and Econometrics, General Health Professions and Physiology. According to data from OpenAlex, Karen Facey has authored 50 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Economics and Econometrics, 11 papers in General Health Professions and 8 papers in Physiology. Recurrent topics in Karen Facey's work include Health Systems, Economic Evaluations, Quality of Life (40 papers), Pharmaceutical Economics and Policy (13 papers) and Biomedical Ethics and Regulation (8 papers). Karen Facey is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (40 papers), Pharmaceutical Economics and Policy (13 papers) and Biomedical Ethics and Regulation (8 papers). Karen Facey collaborates with scholars based in United Kingdom, Italy and Netherlands. Karen Facey's co-authors include Katrine Frønsdal, Marianne Klemp, George Laking, Ian Bradbury, Richard C. Reichman, Ann C. Collier, Roland L. Bassett, Caroline C. Whitacre, David Schoenfeld and Alice Baruch and has published in prestigious journals such as New England Journal of Medicine, British Journal of Cancer and Annals of the Rheumatic Diseases.

In The Last Decade

Karen Facey

46 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine

1996 600 citations Ann C. Collier, Robert W. Coombs et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Facey United Kingdom	22	894	504	499	441	215	50	2.2k
Alec Miners United Kingdom	28	324 0.4×	397 0.8×	1.2k 2.4×	360 0.8×	175 0.8×	101	2.7k
Jessie K. Edwards United States	28	416 0.5×	589 1.2×	831 1.7×	174 0.4×	278 1.3×	204	2.9k
Kathryn A. Phillips United States	37	1.7k 1.9×	1.3k 2.5×	599 1.2×	64 0.1×	649 3.0×	142	5.1k
Ildefonso Hernández‐Aguado Spain	32	169 0.2×	403 0.8×	844 1.7×	421 1.0×	395 1.8×	202	3.9k
Joseph B. Babigumira United States	21	264 0.3×	303 0.6×	303 0.6×	55 0.1×	401 1.9×	76	1.4k
Elliot Marseille United States	29	633 0.7×	685 1.4×	1.3k 2.5×	218 0.5×	365 1.7×	80	3.1k
Timothy S. McNeel United States	37	729 0.8×	452 0.9×	250 0.5×	106 0.2×	834 3.9×	98	5.5k
Jean‐Paul Moatti France	33	466 0.5×	831 1.6×	1.9k 3.7×	598 1.4×	538 2.5×	130	4.1k
Pierre‐Yves Crémieux Canada	18	352 0.4×	364 0.7×	185 0.4×	107 0.2×	74 0.3×	36	1.6k
Stephanie B. Wheeler United States	41	1.3k 1.5×	974 1.9×	215 0.4×	68 0.2×	973 4.5×	323	6.0k

Countries citing papers authored by Karen Facey

Since Specialization

Citations

This map shows the geographic impact of Karen Facey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Facey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Facey more than expected).

Fields of papers citing papers by Karen Facey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Facey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Facey. The network helps show where Karen Facey may publish in the future.

Co-authorship network of co-authors of Karen Facey

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Facey. A scholar is included among the top collaborators of Karen Facey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Facey. Karen Facey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elvidge, Jamie, et al.. (2024). Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop. Frontiers in Pharmacology. 14. 1289365–1289365. 9 indexed citations

Nicod, Elena, Andrew Lloyd, Thomas Morel, et al.. (2022). Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments. Patient. 16(1). 7–17. 8 indexed citations

Capkun, Gorana, Cláudia Furtado, Páll Jónsson, et al.. (2022). Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?. International Journal of Technology Assessment in Health Care. 38(1). e79–e79. 14 indexed citations

Oortwijn, Wija, Don Husereau, Julia Abelson, et al.. (2022). Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. International Journal of Technology Assessment in Health Care. 38(1). e37–e37. 9 indexed citations

Facey, Karen, Jaime Espín, E. Kent, et al.. (2021). Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. PharmacoEconomics. 39(9). 1021–1044. 35 indexed citations

Kent, Seamus, Maximilian Salcher‐Konrad, Stefania Boccia, et al.. (2021). The use of nonrandomized evidence to estimate treatment effects in health technology assessment. Journal of Comparative Effectiveness Research. 10(14). 1035–1043. 17 indexed citations

Nicod, Elena, Michela Meregaglia, Amanda Whittal, et al.. (2021). Consideration of quality of life in the health technology assessments of rare disease treatments. The European Journal of Health Economics. 23(4). 645–669. 11 indexed citations

Whittal, Amanda, Elena Nicod, Sheela Upadhyaya, Michael Drummond, & Karen Facey. (2020). PRO98 Country Specific Approaches to Appraising RARE Disease Treatments: A Case Study Analysis of the IMPACT of Different Processes. Value in Health. 23. S707–S707.

Nicod, Elena, Amanda Whittal, Michael Drummond, & Karen Facey. (2020). Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet Journal of Rare Diseases. 15(1). 189–189. 28 indexed citations

10.

Nicod, Elena, Amanda Whittal, Michael Drummond, & Karen Facey. (2019). PRO77 INTERNATIONAL VARIATIONS IN THE APPRAISAL OF DRUGS FOR RARE DISEASES; WHAT ARE THE MAIN LESSONS?. Value in Health. 22. S855–S855. 1 indexed citations

11.

Facey, Karen, et al.. (2019). Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper. International Journal of Technology Assessment in Health Care. 35(4). 266–272. 18 indexed citations

12.

Annemans, Lieven, Ségolène Aymé, Yann Le Cam, et al.. (2017). Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet Journal of Rare Diseases. 12(1). 50–50. 76 indexed citations

13.

Street, Jackie, Annette Braunack‐Mayer, Karen Facey, Richard Ashcroft, & Janet E. Hiller. (2008). Virtual community consultation? Using the literature and weblogs to link community perspectives and health technology assessment. Health Expectations. 11(2). 189–200. 22 indexed citations

14.

Watt, Amber M., Alun Cameron, Lana Sturm, et al.. (2008). RAPID VERSUS FULL SYSTEMATIC REVIEWS: VALIDITY IN CLINICAL PRACTICE?. ANZ Journal of Surgery. 78(11). 1037–1040. 136 indexed citations

15.

Bradbury, Ian, Karen Facey, George Laking, & P. Sharp. (2003). Investing in new technology: the PET experience. British Journal of Cancer. 89(2). 224–227. 5 indexed citations

16.

Facey, Karen & John A. Lewis. (1998). The management of interim analyses in drug development. Statistics in Medicine. 17(15-16). 1801–1809. 13 indexed citations

17.

Lewis, John A. & Karen Facey. (1998). Statistical shortcomings in licensing applications. Statistics in Medicine. 17(15-16). 1663–1673. 3 indexed citations

18.

Collier, Ann C., Robert W. Coombs, David Schoenfeld, et al.. (1996). Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. New England Journal of Medicine. 334(16). 1011–1018. 600 indexed citations breakdown →

19.

Facey, Karen. (1992). A sequential procedure for a phase II efficacy trial in hypercholesterolemia. Controlled Clinical Trials. 13(2). 122–133. 14 indexed citations

20.

Facey, Karen & John Whitehead. (1990). An improved approximation for calculation of confidence intervals after a sequential clinical trial. Statistics in Medicine. 9(11). 1277–1285. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact